Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India.
The μ-bcr breakpoint connects exon 19 of BCR with ABL giving rise to the e19a2 transcript corresponding to the p230 fusion protein (micro-BCR breakpoint) which is rarely seen in chronic myeloid leukemia (CML) patients. Here we report three patients with p230 fusion protein presenting with different clinical presentations and diagnosed as CML-CP. These patients received Imatinib (tyrosine kinase inhibitor-TKI) and are still in remission.
Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India.
Sudha
S
Sazawal
Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India.
Sunita
S
Chikkara
Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India.
Kanwaljeet
K
Singh
Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India.
Rekha
R
Chaubey
Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India.
Dinesh
D
Chandra
Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India.
Pravas
P
Mishra
Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India.
Manoranjan
M
Mahapatra
Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India.
Tulika
T
Seth
Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India. Electronic address: renusaxena@outlook.com.
Renu
R
Saxena
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D007194:India; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D014158:Transcription, Genetic; D016896:Treatment Outcome
D000970:Antineoplastic Agents; C581634:BCR-ABL1 fusion protein, human; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl
Chronic myeloid leukemia; Major molecular response (MMR); RQ-PCR; RT-PCR; e19a2 BCR–ABL fusion transcript